Madison Street Capital Lands Game changing Deal For ARES Security Corporation

Earlier in the year, Madison Street Capital which is an investment firm sealed a deal on a minority recapitalization for ARES Security Corporation. Madison Street Capital was the sole financial advisor in the deal which included ARES Security Corporation and Corbel Structured Equity Partners which acted as the financing partner. ARES is widely known for its provision of top notch security software products and risk management as well. It is tasked with providing security for the highest priority items in the world. Some of these items include the transportation and energy sectors and complex systems that are controlled by the government.

 

Corbel has gained status as one of the leading companies in strategic equity funds since it was incepted. To date, it controls investments worth $95 million which has been invested in private small market businesses that have potential to be profitable. This particular deal mainly led to the acquisition of a minority investment and the offering of a downgraded debt investment by Corbel. The deal gives Madison Street Capital the opportunity to propel its sales numbers and also take advantage of the upcoming revenue opportunities from Corbel’s broad network of contacts. The company centers on companies that allow it to give operational value through minimal control and refundable investments.

 

About Madison Street Capital

Madison Street Capital is a renowned investment firm situated in Chicago, Illinois. It has global representation with offices in North America, Asia, and Africa. The company has over one decade of extensive experience in the financial and investment sectors. Their vast portfolio consists of business valuation services, mergers and acquisition and corporate tax planning among others. The primary aim of the company is to strategically position their clients to thrive exceptionally in the global market.

 

It has undeterred commitment to delivering advice on financial matters to the public and privately owned business. Their skill and dedication have given Madison Street Capital reputation among its investment partners and clients as well. The firm has confidence in the quality services that its workforce provides through deeply rooted analysis and the ability to provide meticulous resources and recommendations.

 

Madison has centered most of its investments in rising markets which have been determined as the most capable growth engineers for numerous businesses all over the world. Due to the firm’s consistent success and unique investment techniques, they have been awarded the Cross Border Deal of The Year to the success of Madison Street Capital and its investment strategies; they received the International. The award is given by M&A Advisor Awards. In 2017, they also received the Turnaround Awards for Restructuring Deal of the Year.

 

Visit http://madisonstreetcapital.org/ for more information.

 

 

 

 

Laidlaw’s Shady Practices Brought to Light

Anyone that has been following the debacle between Relmada Therapeutics and Laidlaw & Company will be happy to know that a U.S. federal court has issued an order in favor of Relmada Therapeutics. Specifically, the U.S. District Court for the District of Nevada has issued a restraining order against Laidlaw & Company, as well as an injunction to prevent them from continuing to spread false information.

Laidlaw and its principals, Matthew Eitner and James Ahern, have a history of spreading false information and using generally deceitful tactics to try and bully other companies into following their lead. As hopeless as the situation may feel sometimes as an outsider looking in, it’s nice to see that sometimes the courts are willing to take a stand against big business and protect the underdog. In the case of Relmada Therapeutics, the dispute originally took place after Laidlaw made attempts to seize control of Relmada Therapeutics. While it’s true that Laidlaw did at one point serve as an investment banker for Relmada, it’s clear that their two business philosophies are inherently incompatible.

Luckily, the Chief Executive Officer of Relmada Therapeutics agrees with me, as he is quoted as saying that his company’s interests clearly do not coincide with Laidlaw & Company’s. If you’ve never heard the name Laidlaw & Company, you might be forgiven for thinking this is just some overblown dispute between two competing companies. In truth, this dispute gets to a deeper problem within Laidlaw & Company’s business practices and ethics. Specifically, Laidlaw & Company has repeatedly proven in the past that they will exploit anyone or anything in order to make a profit for themselves, regardless of the damage it may cause. This tendency towards the unethical is evident in their dealings with Relmada Therapeutics, but other financial disputes as well. It’s for this reason that the court has had no issue in warning Matthew Eitner and James Ahern to cease spreading false information to try and justify their actions.